Aetna modified CPB 0962 for afamelanotide (Scenesse), effective December 10, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated this coverage policy governing HCPCS code J7352 — afamelanotide implant, 1 mg — for the treatment of erythropoietic protoporphyria (EPP). CPB 0962 Aetna now has clearly defined initial approval criteria and continuation of therapy standards. If your practice implants Scenesse or bills J7352 for commercial Aetna members, this policy sets the rules you'll be held to on every claim.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Afamelanotide (Scenesse) — CPB 0962 |
| Policy Code | CPB 0962 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, Hematology, Rare Disease/Metabolic Disorders |
| Key Action | Confirm biochemical lab documentation — specifically protoporphyrin levels above the reference range — before billing J7352 for any Aetna commercial member |
Aetna Afamelanotide Coverage Criteria and Medical Necessity Requirements 2025
The Aetna afamelanotide coverage policy is narrow by design. Scenesse is an orphan drug treating a rare, debilitating disease. Aetna isn't writing a broad policy here — they're building a tight gate.
To meet medical necessity for initial approval, the member must be an adult with biochemically confirmed erythropoietic protoporphyria. Confirmation isn't clinical impression or symptoms alone. The member must have a protoporphyrin level above the lab reference range in peripheral red blood cells.
That biochemical threshold is the most important sentence in this policy. No lab documentation, no coverage. If your ordering provider doesn't pull that result before treatment, your J7352 claim will deny.
This policy applies to commercial medical plans only. If your Aetna volume includes Medicare Advantage, Medicaid managed care, or any government-funded product, verify separately — CPB 0962 does not govern those lines.
Prior Authorization
This policy doesn't state explicitly that prior authorization is required — but that's not a reason to skip it. Aetna routinely requires prior auth for specialty drugs and implantable biologics. Given the cost of Scenesse and the narrow approved indication, treat prior authorization as mandatory until you have written confirmation otherwise from Aetna for your specific plan type. Call the number on the back of the member's card and get it in writing before the implant procedure.
Continuation of Therapy
Aetna will continue to cover afamelanotide for members who are already on therapy — but only if they're experiencing benefit. "Experiencing benefit" is Aetna's language, and it will drive reauthorization reviews.
Document functional and clinical response at every visit. If a member reports reduced phototoxic pain or improved light tolerance, put it in the chart with specifics. Vague notes won't survive a continued therapy review. Quantify benefit where you can — hours of outdoor light tolerance, reduction in pain events, patient-reported quality of life scores.
Reimbursement for J7352 depends on this documentation surviving scrutiny. Make it airtight from the first implant.
Aetna Afamelanotide Exclusions and Non-Covered Indications
Aetna draws a hard line here. Every indication outside of EPP with confirmed elevated peripheral red blood cell protoporphyrin levels is classified as experimental, investigational, or unproven.
That classification has real consequences. It means no coverage and no appeals path based on off-label use alone. If a provider is using Scenesse for X-linked protoporphyria, congenital erythropoietic porphyria, or any other porphyrin disorder — even a related one — Aetna won't pay under this policy.
The related policies listed in CPB 0962 are telling. Aetna cross-references CPB 0596 (Liver Transplantation) and CPB 0871 (Hematopoietic Cell Transplantation for Inherited Metabolic Disorders). Those references acknowledge that EPP can progress to liver disease and that transplant may eventually be relevant. But they don't expand coverage for Scenesse — they acknowledge that some EPP patients end up on a different clinical path entirely.
Don't bill J7352 for members pursuing those pathways unless the EPP indication itself meets the criteria above. The drug indication and the procedural path are separate coverage questions.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Erythropoietic protoporphyria (EPP) — adult, biochemically confirmed, protoporphyrin level above reference range in peripheral red blood cells | Covered | J7352, E80.0 | Biochemical lab documentation required; confirm prior auth before billing |
| Continuation of EPP therapy — adult, currently on treatment, experiencing clinical benefit | Covered | J7352, E80.0 | Document functional benefit at each visit for reauthorization |
| All other indications (including off-label porphyrin disorders, investigational uses) | Not Covered — Experimental/Investigational | J7352 | No coverage regardless of clinical rationale; appeals unlikely to succeed on off-label grounds |
Aetna Afamelanotide Billing Guidelines and Action Items 2025
These are your concrete steps before and after the December 10, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Audit every active J7352 patient in your Aetna commercial book now. Pull their diagnosis codes and confirm E80.0 (Hereditary erythropoietic porphyria) is on file. If you're billing other porphyria-related codes, flag those accounts immediately — they don't meet criteria under CPB 0962. |
| 2 | Verify biochemical documentation for every patient before the next billing cycle. You need a protoporphyrin level from peripheral red blood cells showing a result above the lab reference range. If that lab result isn't in the chart, get it before you bill J7352 again. |
| 3 | Confirm prior authorization status for all active Aetna commercial members receiving afamelanotide billing. Even if a prior auth was approved before December 10, 2025, check whether the updated policy criteria trigger a new review. Call Aetna's pharmacy or medical benefit line — J7352 may route through either, depending on the plan — and confirm your auth covers the current policy version. |
| 4 | Build a continuation of therapy documentation template. Every reauthorization request needs evidence of benefit. Work with your clinical team to create a structured progress note section that captures: phototoxic reaction frequency, light exposure tolerance, pain scores, and patient-reported functional improvement. Generic notes don't survive utilization review. |
| 5 | Update your charge capture to pair J7352 with E80.0 exclusively for Aetna commercial claims. The other ICD-10 codes listed in the policy data — A49.02 (MRSA infection) and I63.9 (Cerebral infarction, unspecified) — are not EPP diagnoses. Their presence in the policy data is anomalous and doesn't indicate Aetna covers afamelanotide for those conditions. Do not use those codes when billing J7352. Using an unsupported diagnosis code is a direct path to claim denial and potential compliance exposure. |
| 6 | Talk to your compliance officer about the ICD-10 code discrepancy before December 10, 2025. This is the part of CPB 0962 that deserves scrutiny. The policy data includes A49.02 (MRSA, unspecified site) and I63.9 (Cerebral infarction, unspecified) alongside E80.0. Those codes have no clinical relationship to afamelanotide or EPP. If your billing team sees those codes in Aetna's published policy data, get clarification directly from Aetna before assuming they indicate any coverage expansion. They don't — and billing J7352 with those diagnoses would be unsupported. Loop in your compliance officer on this one. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Afamelanotide Under CPB 0962
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J7352 | HCPCS | Afamelanotide implant, 1 mg |
J7352 is the only code in this policy. Each Scenesse implant contains 16 mg, so bill J7352 x16 units per implant — but confirm your unit billing with Aetna's fee schedule and your authorization language before submitting. Unit miscounts are a common source of partial denials on this drug.
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Note |
|---|---|---|
| E80.0 | Hereditary erythropoietic porphyria | The appropriate diagnosis code for EPP — use this when billing J7352 |
| A49.02 | Methicillin resistant Staphylococcus aureus infection, unspecified site | Listed in policy data — no clinical relationship to afamelanotide; do not use with J7352 |
| I63.9 | Cerebral infarction, unspecified | Listed in policy data — no clinical relationship to afamelanotide; do not use with J7352 |
The presence of A49.02 and I63.9 in this policy data is the most confusing element of CPB 0962 as published. These codes have nothing to do with EPP or Scenesse. They may reflect a data entry issue on Aetna's end, a legacy artifact in their policy management system, or something else entirely. Whatever the explanation, do not treat their presence as coverage authorization for those conditions. E80.0 is your diagnosis code for afamelanotide billing. Full stop.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.